Q32 Bio (QTTB) Net Income towards Common Stockholders (2017 - 2026)

Q32 Bio's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 31.02% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at $3.5 million (up 128.47% YoY), while the FY2025 annual figure was $29821.0, up 146.94% from the prior year.
• Net Income towards Common Stockholders was -$7.6 million for Q1 2026 at Q32 Bio, down from $27.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $92.7 million in Q1 2022 to a low of -$34.6 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged -$540026.8 across 5 years, with a median of -$7.6 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 8735.88% in 2022, then slumped 1172.01% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$34.6 million in 2022, then jumped by 177.01% to $26.6 million in 2023, then advanced by 25.76% to $33.5 million in 2024, then fell by 16.55% to $27.9 million in 2025, then tumbled by 127.23% to -$7.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$7.6 million (Q1 2026), $27.9 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.